WallStreetZenWallStreetZen

NASDAQ: DNLI
Denali Therapeutics Inc Stock

$16.60-0.22 (-1.31%)
Updated Apr 18, 2024
DNLI Price
$16.60
Fair Value Price
N/A
Market Cap
$2.31B
52 Week Low
$15.45
52 Week High
$33.31
P/E
-15.66x
P/B
2.24x
P/S
8.92x
PEG
N/A
Dividend Yield
N/A
Revenue
$330.53M
Earnings
-$145.22M
Gross Margin
100%
Operating Margin
-43.93%
Profit Margin
-43.9%
Debt to Equity
0.12
Operating Cash Flow
-$358M
Beta
1.32
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

DNLI Overview

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DNLI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DNLI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DNLI is good value based on its book value relative to its share price (2.24x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
DNLI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DNLI due diligence checks available for Premium users.

Be the first to know about important DNLI news, forecast changes, insider trades & much more!

DNLI News

Valuation

DNLI fair value

Fair Value of DNLI stock based on Discounted Cash Flow (DCF)
Price
$16.60
Fair Value
-$0.07
Undervalued by
24,127.61%
DNLI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

DNLI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-15.66x
Industry
15.68x
Market
41.33x

DNLI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.24x
Industry
5.76x
DNLI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DNLI's financial health

Profit margin

Revenue
$0.0
Net Income
-$119.5M
Profit Margin
0%
DNLI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DNLI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.2B
Liabilities
$123.0M
Debt to equity
0.12
DNLI's short-term assets ($1.06B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DNLI's short-term assets ($1.06B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DNLI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DNLI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$98.7M
Investing
$73.0M
Financing
$4.7M
DNLI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DNLI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
DNLI$2.31B-1.31%-15.66x2.24x
RYTM$2.29B-0.88%-11.91x13.50x
ARVN$2.33B+2.51%-5.18x3.54x
MRUS$2.34B-1.41%-13.49x6.57x
CORT$2.35B-1.48%22.22x4.63x

Denali Therapeutics Stock FAQ

What is Denali Therapeutics's quote symbol?

(NASDAQ: DNLI) Denali Therapeutics trades on the NASDAQ under the ticker symbol DNLI. Denali Therapeutics stock quotes can also be displayed as NASDAQ: DNLI.

If you're new to stock investing, here's how to buy Denali Therapeutics stock.

What is the 52 week high and low for Denali Therapeutics (NASDAQ: DNLI)?

(NASDAQ: DNLI) Denali Therapeutics's 52-week high was $33.31, and its 52-week low was $15.45. It is currently -50.17% from its 52-week high and 7.44% from its 52-week low.

How much is Denali Therapeutics stock worth today?

(NASDAQ: DNLI) Denali Therapeutics currently has 139,160,239 outstanding shares. With Denali Therapeutics stock trading at $16.60 per share, the total value of Denali Therapeutics stock (market capitalization) is $2.31B.

Denali Therapeutics stock was originally listed at a price of $21.45 in Dec 8, 2017. If you had invested in Denali Therapeutics stock at $21.45, your return over the last 6 years would have been -22.61%, for an annualized return of -4.18% (not including any dividends or dividend reinvestments).

How much is Denali Therapeutics's stock price per share?

(NASDAQ: DNLI) Denali Therapeutics stock price per share is $16.60 today (as of Apr 18, 2024).

What is Denali Therapeutics's Market Cap?

(NASDAQ: DNLI) Denali Therapeutics's market cap is $2.31B, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Denali Therapeutics's market cap is calculated by multiplying DNLI's current stock price of $16.60 by DNLI's total outstanding shares of 139,160,239.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.